Health Dictionary Find a Doctor

Mycobacterium abscessus

This page is about clinical aspects of the disease.  For microbiologic aspects of the causative organism(s), see Mycobacterium abscessus causes.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Synonyms and keywords: M. abcessus, non tuberculous mycobacterium, NTM, rapidly growing mycobacterium, RGM

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Mycobacterium abscessus (M. abscessus) is a rapidly growing mycobacterium (RGM) that is a common water contaminant. Mycobacterium abscessus is a bacterium distantly related to the ones that cause tuberculosis and leprosy. It is part of a group known as rapidly growing mycobacteria and is found in water, soil, and dust. It has been known to contaminate medications and products, including medical devices. M. abscessus can cause a variety of infections. Healthcare-associated infections due to this bacterium are usually of the skin and the soft tissues under the skin. It is also a cause of serious lung infections in persons with various chronic lung diseases, such as cystic fibrosis, post-traumatic wound infections, and disseminated cutaneous diseases, mostly in patients with suppressed immune systems.

Historical Perspective

M. abscessus was first isolated in 1953 from gluteal abscesses in a 62-year-old patient who had injured her knee as a child and had a disseminated infection 48 years later.[1] It was until 1992 that M. abscessus is considered a separate organism from Mycobacterium chelonae. The species M. bolletii, named after the late microbiologist and taxonomist Claude Bollet, was described in 2006. In current taxonomy, M. bolletii and M. massiliense (named for Massilia, the ancient Greek and Roman name for Marseille, where the organism was isolated) have been incorporated into M. abscessus subsp. bolletii. [2][3]

Causes

M. abscessus is a bacterium distantly related to the ones that cause tuberculosis and leprosy. It is part of a group known as rapidly growing mycobacteria (RGM) and is found in water, soil, and dust. It has been known to contaminate medications and products, including medical devices.

Epidemiology and Demographics

M. abscessus infection can occur worldwide. Although M. abscessus infection has been reported throughout the United States, South Eastern states such as Florida and Texas have the highest incidence.[4] In July 2014, an outbreak of M. abscessus infection was reported in South Carolina among surgical patients. Moreover, 80% of rapidly growing mycobacterial related respiratory disease are caused by M. abscessus infection in the United States. While infected patients who have no predisposing factors are likely non smoker females older than 60 years of age, M. abscessus infection among patients with predisposing factors occurs at an earlier age.[5] Approximately 15% of patients who have M. abscessus infection also have a co-infection with mycobacterium avium complex (MAC).[5]

Risk Factors

Skin, soft tissue, and bone infection with M. abscessus has been associated with penetrating injuries, open wounds, intramuscular injections, and inappropriate disinfection of medical devices. Some of the risk factors for respiratory M. abscessus infection are chronic lung diseases such as cystic fibrosis and previous untreated mycobacterial infection.

Natural History, Complications and Prognosis

Infection with M. abscessus can lead to skin, soft tissues and bone infections, bronchopulmonary infections, and disseminated infection in non-AIDS immunocompromised patients[6] Minor infections with M. abscessus can resolve either spontaneously or following surgical debridement.[4] The majority of pulmonary M. abscessus infection are chronic and incurable. When pulmonary M. abscessus infection occurs in the absence of any predisposing conditions, the course of the disease is slowly progressive and indolent. Whereas, when the pulmonary infection is associated with underlying predisposing factors, such as gastrointestinal or pulmonary conditions, the disease is rapidly progressive and fulminant.[5]

Diagnosis

Diagnostic Criteria

When symptoms suggestive skin and soft tissues infection with M. abscessus are present, the definitive diagnosis requires the isolation of the organism from the infection site or, in severe cases, from a blood culture. The diagnosis of pulmonary M. abscessus infection requires the presence of clinical, radiological and microbiological diagnostic criteria.[4]

History and Symptoms

Symptoms of of skin and soft tissue infection with M. abscessus (M.abscessus) red/purple, warm, tender to the touch, swollen, and/or painful skin. The most commonly reported symptom in respiratory infection with M.abscessus is cough. Constitutional symptoms increase as the disease progresses. The patient should be asked about any recent history of procedures, such as surgery or injections, as well as any risk factor for the infection.

Physical Examination

The physical exam of patients with skin and soft tissue infection with M. abscessus reveals red, warm, tender to the touch, swollen, and/or painful. Infected areas can also develop boils or pus-filled vesicles. The assessment of vital signs might reveal fever.

Laboratory Findings

To reach a definitive diagnosis, the organism has to be cultured from the infection site or, in severe cases, from a blood culture. The diagnosis is made by growing this bacterium in the laboratory from a sample of the pus or biopsy of the infected area.

Chest X Ray

Chest X-ray findings in patients with pulmonary M. abscessus infection include upper lobe infiltrates, cavitation, and/or patchy, reticulonodular, or mixed interstitial-alveolar opacities. The chest X-ray abnormalities can be bilateral or multilobal.[5][4]

Other Imaging Findings

High-resolution CT (HRCT) scan of the chest might be ordered to assess the pulmonary abnormalities in M. abscessus infection. Abnormal findings may include bronchiectasis, as a result of the infection or as a predisposing factor for it, and/or patchy small nodules.[4]

Treatment

Medical Therapy

The treatment of M. abscessus skin and soft tissue infection includes draining collections of pus, surgical debridement, and administration of combination of antibiotics. M. abscessus has a variable in vitro drug susceptibilities profile; therefore, antibiotic susceptibility testing is required. The treatment of pulmonary M. abscessus infection includes a combination of antibiotics and surgical resection of the localized disease. M. abscessus infection is treated by a macrolide-based multidrug antibiotic regimen. The duration of the antibiotic regimen depends on the site of infection: 2-4 months in pulmonary infection, at least 4 months in skin and soft tissue infection, and 6 months for bone infection.

Surgery

The treatment of M. abscessus skin and soft tissue infection includes draining collections of pus, surgical debridement, and administration of combination of antibiotics.[4] Surgical resection should be considered particularly in extensive disease or unefficacious antibiotic therapy. In addition, removal of foreign bodies that are likely the source of the mycobacterium, such as catheters or breast implants, is advised.[4] The treatment of pulmonary M. abscessus infection also includes a combination of antibiotics for a prolonged period of time as well as surgical resection of the localized disease. The majority of pulmonary M. abscessus infection are chronic and incurable. Successful treatment is more likely if the patient undergoes surgical resection following the initial antibiotic therapy.[4]

Primary Prevention

Primary prevention of M. abscessus requires avoiding exposure to tap water or tap water ice of surgical wounds, intravenous catheters, and injection sites. Tap water or tap water ice should not be used in the operating rooms, particularly in cardiac surgeries or mammoplasty, or in outpatient clinics where plastic surgery procedures are performed.[4] Subjects should avoid receiving procedures or injections by unlicensed persons.

References

  1. MOORE M, FRERICHS JB (1953). “An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, Mycobacterium abscessus, n. sp”. J Invest Dermatol. 20 (2): 133–69. PMID 13035193.
  2. Etymologia: Mycobacterium abscessus subsp. bolletii. Emerg Infect Dis [Internet]. 2014 Mar [February 20, 2014]. http://dx.doi.org/10.3201/eid2003.ET2003
  3. CDC.gov Etymologia: Mycobacterium abscessus subsp. bolletii
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F; et al. (2007). “An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases”. Am J Respir Crit Care Med. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290.
  5. 5.0 5.1 5.2 5.3 Griffith DE, Girard WM, Wallace RJ (1993). “Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients”. Am Rev Respir Dis. 147 (5): 1271–8. doi:10.1164/ajrccm/147.5.1271. PMID 8484642.
  6. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B (2012). “Mycobacterium abscessus: a new antibiotic nightmare”. J Antimicrob Chemother. 67 (4): 810–8. doi:10.1093/jac/dkr578. PMID 22290346.


Template:WikiDoc Sources

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Mycobacterium abscessus (M. abscessus) was first isolated in 1953 from gluteal abscesses in a 62-year-old patient who had injured her knee as a child and had a disseminated infection 48 years later.[1] It was until 1992 that M. abscessus is considered a separate organism from Mycobacterium chelonae. The species M. bolletii, named after the late microbiologist and taxonomist Claude Bollet, was described in 2006. In current taxonomy, M. bolletii and M. massiliense (named for Massilia, the ancient Greek and Roman name for Marseille, where the organism was isolated) have been incorporated into M. abscessus subsp. bolletii. [2][3]

References


Template:WikiDoc Sources

Causes
This page is about microbiologic aspects of the organism(s).  For clinical aspects of the disease, see Mycobacterium abscessus.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Mycobacterium abscessus (M. abscessus) is a bacterium distantly related to the ones that cause tuberculosis and leprosy. It is part of a group known as rapidly growing mycobacteria (RGM) and is found in water, soil, and dust. It has been known to contaminate medications and products, including medical devices.

Taxonomy

Transmission

Infection with M. abscessus is usually caused by injections of substances contaminated with the bacterium or through invasive medical procedures employing contaminated equipment or material. Infection can also occur after accidental injury where the wound is contaminated by soil. There is very little risk of transmission from person to person.

M. abscessus is relatively resistant to chlorine and standard disinfectant.[1]

Microscopy

  • Gram-positive, non-motile and acid-fast rods (1.0-2.5µm x 0.5µm).

Colony Characteristics

  • Colonies on Löwenstein-Jensen media may occur as smooth as well as rough, white or greyish and nonphotochromogenic

Physiology

  • Growth at 28°C and 37°C after 7 days but not at 43°C
  • On MacConkey agar at 28°C and even 37°C
  • Tolerance to 5% NaCl and 500mg/l hydroxylamine (Ogawa egg medium) and 0.2% picrate (Sauton agar medium)
  • Positive degradation of p-aminosalicylate
  • Production of arylsulfatase but not of nitrate reductase and Tween 80 hydrolase
  • Negative iron uptake test
  • No utilization of fructose, glucose, oxalate and citrate as sole carbon sources

Differential Characteristics

  • M. abscessus and M. chelonae can be distinguished from M. fortuitum or M. peregrinum by their failure to reduce nitrate and to take up iron.
  • Tolerance to 5% NaCl in Löwenstein-Jensen media tolerance to 0.2% picrate in Sauton agar and non-utilisation of citrate as a sole carbon source are characteristics that distinguish M. abscessus from M. chelonae.
  • M. abscessus and M. chelonae sequevar I share an identical sequence in the 54-510 region of 16S rRNA, However, both species can be differentiated by their hsp65 or ITS sequences

Subspecies

  • M. abscessus sensu stricto
  • Mycobacterium massiliense[2]
  • Mycobacterium bolletii[3]

Strains

ATCC 19977 = CCUG 20993 = CIP 104536 = DSM 44196 = JCM 13569 = NCTC 13031

Genetics

A draft genome sequence of M. abscessus subsp. bolletii BDT was completed in 2012.[4] More than 25 different strains of this subspecies, including pathogenic isolates, have had their genomes sequenced.[5]

Resistance to Antibiotics

Intrinsic Factors

Acquired Factors

  • Mutation of the genes that code the antibiotic targets[6]

References

  1. Wallace RJ, Brown BA, Griffith DE (1998). “Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria”. Annu Rev Microbiol. 52: 453–90. doi:10.1146/annurev.micro.52.1.453. PMID 9891805.
  2. Adékambi T, Reynaud-Gaubert M, Greub G, Gevaudan MJ, La Scola B, Raoult D; et al. (2004). “Amoebal coculture of “Mycobacterium massiliense” sp. nov. from the sputum of a patient with hemoptoic pneumonia”. J Clin Microbiol. 42 (12): 5493–501. doi:10.1128/JCM.42.12.5493-5501.2004. PMC 535245. PMID 15583272.
  3. Adékambi T, Berger P, Raoult D, Drancourt M (2006). “rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov”. Int J Syst Evol Microbiol. 56 (Pt 1): 133–43. doi:10.1099/ijs.0.63969-0. PMID 16403878.
  4. Choi, G.-E.; Cho, Y.-J.; Koh, W.-J.; Chun, J.; Cho, S.-N.; Shin, S. J. (24 April 2012). “Draft Genome Sequence of Mycobacterium abscessus subsp. bolletii BDT”. Journal of Bacteriology. 194 (10): 2756–2757. doi:10.1128/JB.00354-12.
  5. Davidson, Rebecca M. (December 2013). “Phylogenomics of Brazilian epidemic isolates of Mycobacterium abscessus subsp. bolletii reveals relationships of global outbreak strains”. Infection, Genetics and Evolution. 20: 292–297. doi:10.1016/j.meegid.2013.09.012. Unknown parameter |coauthors= ignored (help)
  6. 6.0 6.1 6.2 6.3 6.4 Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B (2012). “Mycobacterium abscessus: a new antibiotic nightmare”. J Antimicrob Chemother. 67 (4): 810–8. doi:10.1093/jac/dkr578. PMID 22290346.


Template:WikiDoc Sources

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Mycobacterium abscessus (M. abscessus) infection can occur worldwide. Although M. abscessus infection has been reported throughout the United States, South Eastern states such as Florida and Texas have the highest incidence.[1] In July 2014, an outbreak of M. abscessus infection was reported in South Carolina among surgical patients. Moreover, 80% of rapidly growing mycobacterial related respiratory disease are caused by M. abscessus infection in the United States. While infected patients who have no predisposing factors are likely non smoker females older than 60 years of age, M. abscessus infection among patients with predisposing factors occurs at an earlier age.[2] Approximately 15% of patients who have M. abscessus infection also have a co-infection with mycobacterium avium complex (MAC).[2]

References

  1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F; et al. (2007). “An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases”. Am J Respir Crit Care Med. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290.
  2. 2.0 2.1 Griffith DE, Girard WM, Wallace RJ (1993). “Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients”. Am Rev Respir Dis. 147 (5): 1271–8. doi:10.1164/ajrccm/147.5.1271. PMID 8484642.


Template:WikiDoc Sources

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Skin, soft tissue, and bone infection with Mycobacterium abscessus (M. abscessus) has been associated with penetrating injuries, open wounds, intramuscular injections, and inappropriate disinfection of medical devices. Some of the risk factors for respiratory M. abscessus infection are chronic lung diseases such as cystic fibrosis and previous untreated mycobacterial infection.

Risk Factors

Skin and Soft Tissue Infection

  • Open wounds
  • Penetrating injury
  • Surgical tourism[1]
  • Laparoscopic surgery[1]
  • Cosmetic surgery[2]
  • Intramuscular injections[3][4][5][6]
    • Inappropriate skin disinfection
    • Inappropriate sterilization of the equipment[7]
    • Contaminated solutions
  • Contaminated municipal or water supply[8][9]
  • Acupuncture (contaminated solution used to clean the physical therapy device)[10]
  • Dialysis[11][12]
  • Bronchoscopy[8]
    • Inadequate desinfection of the bronchoscope
    • Contaminated local anesthesia solution
    • Contaminated tap water
    • Contaminated antimicrobial solution
  • Wading and public pool exposure (hand-and-foot disease)[13][14]

Bronchopulmonary Infection

Disseminated Infection

  • Non AIDS-related immune suppression[19][20]

References

  1. 1.0 1.1 Viana-Niero C, Lima KV, Lopes ML, Rabello MC, Marsola LR, Brilhante VC; et al. (2008). “Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures”. J Clin Microbiol. 46 (3): 850–5. doi:10.1128/JCM.02052-07. PMC 2268380. PMID 18174307.
  2. Safranek TJ, Jarvis WR, Carson LA, Cusick LB, Bland LA, Swenson JM; et al. (1987). “Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution”. N Engl J Med. 317 (4): 197–201. doi:10.1056/NEJM198707233170403. PMID 3600710.
  3. Kim HY, Yun YJ, Park CG, Lee DH, Cho YK, Park BJ; et al. (2007). “Outbreak of Mycobacterium massiliense infection associated with intramuscular injections”. J Clin Microbiol. 45 (9): 3127–30. doi:10.1128/JCM.00608-07. PMC 2045247. PMID 17626174.
  4. Borghans JG, Stanford JL (1973). “Mycobacterium chelonei in abscesses after injection of diphtheria-pertussis-tetanus-polio vaccine”. Am Rev Respir Dis. 107 (1): 1–8. PMID 4683319.
  5. Inman PM, Beck A, Brown AE, Stanford JL (1969). “Outbreak of injection abscesses due to Mycobacterium abscessus”. Arch Dermatol. 100 (2): 141–7. PMID 5797954.
  6. Villanueva A, Calderon RV, Vargas BA, Ruiz F, Aguero S, Zhang Y; et al. (1997). “Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction”. Clin Infect Dis. 24 (6): 1147–53. PMID 9195073.
  7. Wenger JD, Spika JS, Smithwick RW, Pryor V, Dodson DW, Carden GA; et al. (1990). “Outbreak of Mycobacterium chelonae infection associated with use of jet injectors”. JAMA. 264 (3): 373–6. PMID 2362334.
  8. 8.0 8.1 Wallace RJ, Brown BA, Griffith DE (1998). “Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria”. Annu Rev Microbiol. 52: 453–90. doi:10.1146/annurev.micro.52.1.453. PMID 9891805.
  9. Thomson R, Tolson C, Sidjabat H, Huygens F, Hargreaves M (2013). “Mycobacterium abscessus isolated from municipal water – a potential source of human infection”. BMC Infect Dis. 13: 241. doi:10.1186/1471-2334-13-241. PMC 3668184. PMID 23705674.
  10. Koh SJ, Song T, Kang YA, Choi JW, Chang KJ, Chu CS; et al. (2010). “An outbreak of skin and soft tissue infection caused by Mycobacterium abscessus following acupuncture”. Clin Microbiol Infect. 16 (7): 895–901. doi:10.1111/j.1469-0691.2009.03026.x. PMID 19694761.
  11. Bolan G, Reingold AL, Carson LA, Silcox VA, Woodley CL, Hayes PS; et al. (1985). “Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers”. J Infect Dis. 152 (5): 1013–9. PMID 4045242.
  12. Lowry PW, Beck-Sague CM, Bland LA, Aguero SM, Arduino MJ, Minuth AN; et al. (1990). “Mycobacterium chelonae infection among patients receiving high-flux dialysis in a hemodialysis clinic in California”. J Infect Dis. 161 (1): 85–90. PMID 2295862.
  13. Dytoc MT, Honish L, Shandro C, Ting PT, Chui L, Fiorillo L; et al. (2005). “Clinical, microbiological, and epidemiological findings of an outbreak of Mycobacterium abscessus hand-and-foot disease”. Diagn Microbiol Infect Dis. 53 (1): 39–45. doi:10.1016/j.diagmicrobio.2005.03.010. PMID 16054324.
  14. Sinagra JL, Kanitz EE, Cerocchi C, Cota C, Fantetti O, Prignano G; et al. (2014). “Mycobacterium abscessus hand-and-foot disease in children: rare or emerging disease?”. Pediatr Dermatol. 31 (3): 292–7. doi:10.1111/pde.12333. PMID 24758202.
  15. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, Offredo C, Guillemot D, Halley S; et al. (2003). “Mycobacterium abscessus and children with cystic fibrosis”. Emerg Infect Dis. 9 (12): 1587–91. doi:10.3201/eid0912.020774. PMC 3034322. PMID 14720400.
  16. Radhakrishnan DK, Yau Y, Corey M, Richardson S, Chedore P, Jamieson F; et al. (2009). “Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors”. Pediatr Pulmonol. 44 (11): 1100–6. doi:10.1002/ppul.21106. PMID 19830845.
  17. 17.0 17.1 17.2 17.3 Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F; et al. (2007). “An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases”. Am J Respir Crit Care Med. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290.
  18. Benwill J, Babineaux M, Sarria JC (2010). “Pulmonary Mycobacterium abscessus in an AIDS patient”. Am J Med Sci. 339 (5): 495–6. doi:10.1097/MAJ.0b013e3181d96ad7. PMID 20375687.
  19. Babalık A, Kuyucu T, Ordu EN, Ernam D, Partal M, Köksalan K (2012). “Non-tuberculous mycobacteria infection: 75 cases”. Tuberk Toraks. 60 (1): 20–31. PMID 22554363.
  20. Lambertucci JR, Borges AH, Voieta I (2011). “Disseminated Mycobacterium abscessus infection in an AIDS patient”. Rev Soc Bras Med Trop. 44 (2): 265. PMID 21552751.


Template:WikiDoc Sources

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Infection with mycobacterium abscessus (M. abscessus) can lead to skin, soft tissues and bone infections, bronchopulmonary infections, and disseminated infection in non-AIDS immunocompromised patients[1] Minor infections with M. abscessus can resolve either spontaneously or following surgical debridement.[2] The majority of pulmonary M. abscessus infection are chronic and incurable. When pulmonary M. abscessus infection occurs in the absence of any predisposing conditions, the course of the disease is slowly progressive and indolent. Whereas, when the pulmonary infection is associated with underlying predisposing factors, such as gastrointestinal or pulmonary conditions, the disease is rapidly progressive and fulminant.[3]

Natural History, Complications and Prognosis

Infection with M. abscessus can lead to:

Skin and Soft Tissue Infection

Minor infections with M. abscessus can resolve either spontaneously or following surgical debridement. In the absence of therapy, abscesses that occur after injection of the organism may last up to 8 to 12 months until they resolve spontaneously.[2]

M. abscessus hand-and-foot disease has been described in the pediatric population with wading and public pool exposure.[5][6] The disease is characterized by self limited tender, erythematous, pustules, papules, and abscesses in the hands and feet.[5][6]

Pulmonary Infection

M. abscessus is the most common non tuberculosis mycobacterial infection in cystic fibrosis.[9] Chronic infection with M. abscessus is associated with a decline in lung function among patients with cystic fibrosis.[10] The most commonly reported symptom is cough. Constitutional symptoms increase as the disease progresses. The only effective long-term therapy for M. abscessus was reported to be surgical resection of the localized disease.[3] Death may occur in these patients (mortality in ~14% of patients) due to respiratory failure secondary to the progressive lung disease.[3]

When pulmonary M. abscessus infection occurs in the absence of any predisposing conditions, the course of the disease is slowly progressive and indolent. Whereas, when the pulmonary infection is associated with underlying predisposing factors, such as gastrointestinal or pulmonary conditions, the disease is rapidly progressive and fulminant.[3]

The majority of pulmonary M. abscessus infection are chronic and incurable. Successful treatment is more likely if the disease is limited and if the patient undergoes surgical resection following the initial antibiotic therapy.[2]

References

  1. 1.0 1.1 1.2 Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B (2012). “Mycobacterium abscessus: a new antibiotic nightmare”. J Antimicrob Chemother. 67 (4): 810–8. doi:10.1093/jac/dkr578. PMID 22290346.
  2. 2.0 2.1 2.2 2.3 Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F; et al. (2007). “An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases”. Am J Respir Crit Care Med. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290.
  3. 3.0 3.1 3.2 3.3 Griffith DE, Girard WM, Wallace RJ (1993). “Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients”. Am Rev Respir Dis. 147 (5): 1271–8. doi:10.1164/ajrccm/147.5.1271. PMID 8484642.
  4. Hoffman PC, Fraser DW, Robicsek F, O’Bar PR, Mauney CU (1981). “Two outbreaks of sternal wound infection due to organisms of the Mycobacterium fortuitum complex”. J Infect Dis. 143 (4): 533–42. PMID 7240799.
  5. 5.0 5.1 5.2 Dytoc MT, Honish L, Shandro C, Ting PT, Chui L, Fiorillo L; et al. (2005). “Clinical, microbiological, and epidemiological findings of an outbreak of Mycobacterium abscessus hand-and-foot disease”. Diagn Microbiol Infect Dis. 53 (1): 39–45. doi:10.1016/j.diagmicrobio.2005.03.010. PMID 16054324.
  6. 6.0 6.1 6.2 Sinagra JL, Kanitz EE, Cerocchi C, Cota C, Fantetti O, Prignano G; et al. (2014). “Mycobacterium abscessus hand-and-foot disease in children: rare or emerging disease?”. Pediatr Dermatol. 31 (3): 292–7. doi:10.1111/pde.12333. PMID 24758202.
  7. Garcia DC, Sandoval-Sus J, Razzaq K, Young L (2013). “Vertebral osteomyelitis caused by Mycobacterium abscessus”. BMJ Case Rep. 2013. doi:10.1136/bcr-2013-009597. PMID 23925676.
  8. Ding LW, Lai CC, Lee LN, Hsueh PR (2006). “Abdominal nontuberculous mycobacterial infection in a university hospital in Taiwan from 1997 to 2003”. J Formos Med Assoc. 105 (5): 370–6. doi:10.1016/S0929-6646(09)60132-7. PMID 16638646.
  9. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, Offredo C, Guillemot D, Halley S; et al. (2003). “Mycobacterium abscessus and children with cystic fibrosis”. Emerg Infect Dis. 9 (12): 1587–91. doi:10.3201/eid0912.020774. PMC 3034322. PMID 14720400.
  10. Esther CR, Esserman DA, Gilligan P, Kerr A, Noone PG (2010). “Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis”. J Cyst Fibros. 9 (2): 117–23. doi:10.1016/j.jcf.2009.12.001. PMC 3837580. PMID 20071249.


Template:WikiDoc Sources

Diagnosis

Diagnosis

Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | Other Imaging Findings

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention


Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH